Is Prometrium Safe While Trying to Conceive? What Women Need to Know

What Is Prometrium and Why Is It Used While Trying to Conceive?

Prometrium is the brand name for oral micronized progesterone, a bioidentical form of the hormone your ovaries produce naturally after ovulation. It is not a synthetic progestin. That distinction matters clinically because micronized progesterone more closely mirrors your own endogenous hormone and carries a different safety profile than older synthetic progestins like medroxyprogesterone acetate.

During the luteal phase, which runs from ovulation to either your period or implantation, your corpus luteum produces progesterone to prepare the uterine lining for a fertilized egg. If progesterone output is insufficient, the lining may not sustain an early pregnancy. This is the physiological rationale behind luteal phase support.

How the Menstrual Cycle Changes the Clinical Picture

Progesterone peaks between days 18-22 of a typical 28-day cycle. A serum mid-luteal progesterone below 10 ng/mL is often used as a threshold suggesting inadequate luteal function, though this cutoff is debated and single measurements are unreliable due to pulsatile secretion. Women with PCOS, hypothyroidism, hyperprolactinemia, or cycles shorter than 24 days are at higher risk of a short luteal phase. If any of these conditions apply to you, your prescriber may be more likely to recommend supplementation.

What Prometrium Is FDA-Approved For

The FDA label for Prometrium lists two approved indications: prevention of endometrial hyperplasia in postmenopausal women on estrogen therapy, and treatment of secondary amenorrhea. Luteal phase support while trying to conceive is off-label. Off-label prescribing is legal and common in reproductive medicine; the ASRM Practice Committee explicitly addresses this use, as described below.

Is Prometrium Safe While Trying to Conceive? What the Evidence Shows

The short answer: observational human data are reassuring. No pattern of major congenital malformations has been consistently linked to micronized progesterone exposure during the periconceptional window or first trimester.

Human Data

The largest body of evidence comes from assisted reproductive technology (ART) cycles, where luteal phase supplementation with progesterone is standard practice. A 2021 Cochrane review by van der Linden et al. covering more than 80 randomized trials confirmed that vaginal progesterone increases live birth rates in IVF cycles compared with placebo or no treatment, without identifying a teratogenic signal. The review included tens of thousands of women and is the most comprehensive dataset we have.

For women trying to conceive naturally with a history of recurrent pregnancy loss, the PRISM trial published in the New England Journal of Medicine in 2019 randomized 836 women with unexplained recurrent miscarriage to vaginal micronized progesterone 400 mg twice daily or placebo from the time of a positive pregnancy test through 16 weeks. The live birth rate was 72% in the progesterone group versus 67% in the placebo group, a difference that was not statistically significant in the overall cohort. A pre-specified subgroup of women with three or more prior losses showed a potential benefit, though the trial was not powered for this subgroup. Neonatal outcomes were similar between groups.

The PROMISE trial, an earlier double-blind RCT of 836 women with unexplained recurrent miscarriage, also found no significant improvement in live birth rate with progesterone supplementation versus placebo, and no increase in fetal anomalies.

What Is Extrapolated vs. Directly Studied

Most safety data come from IVF populations, not spontaneous-conception TTC populations. Doses used in IVF luteal support (typically 200-600 mg vaginally per day) are higher than doses used in natural cycles. Extrapolating reassurance from IVF data to lower-dose natural-cycle use is clinically reasonable but not perfectly direct. Women trying to conceive without ART are underrepresented in high-quality safety trials. This is an acknowledged evidence gap. Your clinician is making a judgment call based on biological plausibility and available data, not a head-to-head comparison in your exact situation.

Animal Data

High-dose animal studies referenced in the Prometrium label showed fetal virilization (masculinization of female fetuses) at doses far exceeding clinical use. These findings have not been replicated in human observational studies at therapeutic doses, and bioidentical progesterone is not androgenic in the way some synthetic progestins are. The FDA's former Pregnancy Category B designation (adequate and well-controlled studies in pregnant women have not demonstrated a risk) applies here, though the FDA replaced letter categories with narrative labeling in 2015.

How Prometrium Is Used in TTC: Doses, Timing, and Routes

Prometrium capsules are designed for oral use, but in reproductive medicine they are very commonly used vaginally (off-label) because vaginal administration produces higher local uterine concentrations with lower systemic exposure and fewer sedative side effects.

Typical Dosing Scenarios

| Clinical Scenario | Common Dose | Timing | Route | |---|---|---|---| | Luteal phase support (natural cycle) | 100-200 mg once or twice daily | Start 2-3 days after confirmed ovulation | Vaginal or oral | | IVF luteal support | 200-400 mg twice daily | Start day of or day after egg retrieval | Vaginal (most common) | | Recurrent pregnancy loss prevention | 200-400 mg twice daily | From positive pregnancy test through 12-16 weeks | Vaginal | | Short luteal phase / low progesterone | 100-200 mg at bedtime | After ovulation confirmation | Oral or vaginal |

Doses at the lower end (100-200 mg orally) are used when the goal is modest luteal support in a natural cycle. ASRM Practice Committee guidelines state that progesterone supplementation is required in IVF cycles because the retrieval process removes the granulosa cells that form the corpus luteum, eliminating endogenous progesterone production.

Oral vs. Vaginal: Why Route Matters for Women

Oral Prometrium undergoes extensive first-pass hepatic metabolism. A 200 mg oral dose produces a serum progesterone level far lower than a 200 mg vaginal dose. The first-uterine-pass effect means vaginal progesterone preferentially concentrates in the endometrium. For women who need endometrial priming and are sensitive to the sedating effects of oral progesterone (a known and common side effect due to neurosteroid metabolites), vaginal administration is often better tolerated. If you are using Prometrium capsules vaginally, know that this is off-label use of an oral formulation, and dedicated vaginal progesterone products (Endometrin, Crinone) exist for this purpose.

Pregnancy and Lactation Safety: What You Need to Know Before Starting

This section is required reading if you are actively trying to conceive, currently pregnant, or planning to breastfeed. These are the facts, not reassurances.

Pregnancy Safety

Progesterone is the hormone that sustains early pregnancy. Your corpus luteum produces it; the placenta takes over at approximately 8-10 weeks of gestation. Supplementing with bioidentical progesterone during this window is physiologically congruent.

The current FDA-approved labeling for Prometrium states: "Prometrium Capsules should not be used in women with any of the following conditions: known sensitivity to Prometrium Capsules (micronized progesterone)." On pregnancy, the label notes available human data are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. At very high animal doses, fetal virilization was observed but is not considered relevant to human therapeutic dosing.

No study has shown that micronized progesterone at clinical doses causes congenital anomalies. The PRISM and PROMISE trials combined enrolled more than 1,600 women and found no increase in fetal anomalies compared with placebo.

Prometrium capsules contain peanut oil. Women with peanut allergy should not use them.

Lactation and Breastfeeding

LactMed (National Library of Medicine) classifies progesterone as compatible with breastfeeding. Progesterone transfers into breast milk at low levels. It is a naturally occurring hormone already present in the milk of lactating women. No adverse effects on nursing infants have been reported. High doses of progesterone may theoretically reduce milk supply by suppressing prolactin action, but this concern is primarily theoretical at the doses used postpartum and has not been demonstrated in clinical studies.

If you are breastfeeding and prescribed Prometrium for postpartum luteal support or another indication, discuss the timing with your provider, particularly if you are also working to establish milk supply in the early postpartum weeks.

Contraception Considerations

Prometrium does not provide contraception. If you are prescribed it for luteal phase support in a monitored natural cycle, you are being given it specifically to support a possible conception, so this is not relevant. If you are prescribed it for another reason (such as cycle regulation or HRT) and do not want to become pregnant, continue your chosen contraceptive method.

Who Is Prometrium While TTC Right For and Who Should Think Twice

Women Most Likely to Benefit

• Women with confirmed luteal phase deficiency on serial progesterone measurements or endometrial biopsy
• Women undergoing IVF or other ART cycles, where supplementation is standard of care per ASRM
• Women with a history of recurrent pregnancy loss (two or more consecutive losses), particularly those with three or more losses based on subgroup signals from PRISM
• Women with PCOS, in whom anovulatory or oligo-ovulatory cycles may produce inadequate corpus luteal function after ovulation induction
• Women with hypothyroidism that is undertreated, once thyroid function is optimized (thyroid disease itself, not just progesterone deficiency, may be the driver)

Women Who Should Not Use Prometrium

• Known or suspected peanut allergy (capsules contain peanut oil)
• Undiagnosed abnormal vaginal bleeding
• Active or history of arterial thromboembolic disease (stroke, MI) related to progestogen use
• Known or suspected hormone-sensitive cancer
• Active liver disease or known liver dysfunction
• Known hypersensitivity to progesterone or any capsule ingredient

Life Stage Perspective

Reproductive years, actively TTC. This is the primary population discussed throughout this article. Prometrium is used here for luteal support in natural cycles, ovulation induction cycles (Clomid or letrozole), and ART.

Perimenopause. Women who are perimenopausal and still trying to conceive (a reality for many women in their early-to-mid 40s) may have shorter luteal phases and lower progesterone output. Prometrium may be used, but the underlying issue of diminished ovarian reserve often limits its effectiveness. The FDA-approved HRT indication becomes relevant only after menopause.

Postpartum. Some women receive progesterone for cycle regulation after a pregnancy loss or in preparation for a frozen embryo transfer. Breastfeeding compatibility (see above) is reassuring, but timing relative to milk establishment matters.

Prometrium, PCOS, and Luteal Phase Support

PCOS deserves its own discussion because it is the most common ovulatory disorder affecting reproductive-age women, present in 6-12% of women of reproductive age by the Rotterdam criteria.

Women with PCOS frequently cycle irregularly or not at all. When ovulation induction with letrozole or clomiphene is used, the resulting corpus luteum may produce adequate progesterone in many cycles. Still, some reproductive endocrinologists add luteal phase support empirically in stimulated cycles. A 2023 meta-analysis in Fertility and Sterility found no statistically significant improvement in live birth rates with routine luteal phase support after ovulation induction with oral agents in women with PCOS, suggesting this practice should be individualized rather than universal.

Women with PCOS also have a higher baseline rate of early pregnancy loss. Addressing insulin resistance and androgen excess before conception, rather than relying solely on progesterone supplementation, gives a more complete approach to loss prevention.

Side Effects of Prometrium That Affect Women Specifically

Progesterone metabolizes into neurosteroids, particularly allopregnanolone, which act on GABA-A receptors. This produces the sedation that many women notice with oral Prometrium, particularly at the 200 mg dose. Taking it at bedtime reduces functional impairment.

Common side effects include:

• Drowsiness and dizziness (most common with oral route, less with vaginal)
• Breast tenderness, which can mimic early pregnancy symptoms
• Bloating and water retention
• Mood changes, including low mood or irritability in some women
• Vaginal discharge (if used vaginally)
• Headache

A specific caution for women: because breast tenderness, nausea, and fatigue are also early pregnancy symptoms, Prometrium can make it difficult to interpret your own body's signals in the two-week wait. A serum beta-hCG is more reliable than symptom-tracking to confirm pregnancy.

Prometrium vs. Other Progesterone Options: What Reproductive Medicine Uses

| Product | Formulation | Route | Key Use | |---|---|---|---| | Prometrium 100/200 mg | Micronized progesterone in peanut oil capsule | Oral or vaginal (off-label) | Natural cycles, perimenopause HRT | | Endometrin 100 mg | Micronized progesterone vaginal insert | Vaginal | IVF luteal support (FDA-approved) | | Crinone 8% | Progesterone vaginal gel | Vaginal | IVF luteal support (FDA-approved) | | Prochieve 8% | Progesterone vaginal gel | Vaginal | Supplementation in ART | | Hydroxyprogesterone caproate (Makena) | Synthetic progestin | IM injection | Preterm birth prevention (17-OHPC) |

Prometrium (oral/vaginal capsule) is often the most accessible and lowest-cost option for women in natural TTC cycles. Its main limitation is the peanut-oil vehicle and the sedation profile if taken orally.

What Your Prescriber Is Weighing When They Offer or Decline Prometrium

Prescribers working in reproductive medicine balance several considerations you deserve to understand explicitly.

First, the benefit signal for progesterone supplementation in natural-conception TTC without confirmed luteal phase defect or prior losses is weak. A 2015 Cochrane review on luteal phase support in natural and stimulated cycles found insufficient evidence to support routine use in unstimulated cycles.

Second, the harm signal is also weak. The available human data do not show teratogenicity at clinical doses.

Third, the cost and burden to you are real. Prometrium is not cheap without insurance coverage, and starting and stopping a medication during the emotionally demanding TTC period adds complexity.

The prescriber is often making a shared decision with you, weighing low-level evidence of possible benefit against low-level evidence of harm and real but manageable cost and side effects. If your prescriber explains this tradeoff explicitly, that is a sign of honest, evidence-based care.

As stated in the ASRM Practice Committee Educational Bulletin on progesterone supplementation: "Progesterone supplementation is necessary when using GnRH agonist or antagonist protocols for IVF, and should be considered in other ART procedures where the luteal phase may be compromised."

This language, "necessary" in ART, "should be considered" in other scenarios, reflects the gradation of evidence that exists.

Questions to Ask Your Reproductive Endocrinologist or OB-GYN

Before starting Prometrium while TTC, bring these specific questions:

1. Have you measured my mid-luteal serum progesterone, and what was the result?
2. Is my use of Prometrium for a confirmed luteal phase deficiency or as empirical support?
3. Should I use the oral or vaginal route given my specific situation?
4. Do I have a peanut allergy that makes this formulation unsuitable?
5. At what serum progesterone level or gestational age will you stop supplementation if I become pregnant?
6. Should I also be tested for thyroid function, prolactin, and autoimmune markers before we rely on progesterone supplementation?